LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Exportin 1 inhibition as antiviral therapy.

    Uddin, Md Hafiz / Zonder, Jeffrey A / Azmi, Asfar S

    Drug discovery today

    2020  Volume 25, Issue 10, Page(s) 1775–1781

    Abstract: ... nucleocytoplasmic transport with exportin 1 (XPO1) inhibitors originally developed as anticancer drugs can quarantine key ... using the XPO1 inhibitor selinexor as a therapy for COVID-19 infection are in progress. ... and immunopathogenicity. These observations support the concept of the inhibition of nuclear export ...

    Abstract Coronavirus 2019 (COVID-19; caused by Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV-2) is a currently global health problem. Previous studies showed that blocking nucleocytoplasmic transport with exportin 1 (XPO1) inhibitors originally developed as anticancer drugs can quarantine key viral accessory proteins and genomic materials in the nucleus of host cell and reduce virus replication and immunopathogenicity. These observations support the concept of the inhibition of nuclear export as an effective strategy against an array of viruses, including influenza A, B, and SARS-CoV. Clinical studies using the XPO1 inhibitor selinexor as a therapy for COVID-19 infection are in progress.
    MeSH term(s) Active Transport, Cell Nucleus ; Animals ; Antiviral Agents/therapeutic use ; COVID-19/immunology ; COVID-19/metabolism ; COVID-19/virology ; Cell Nucleus/drug effects ; Cell Nucleus/immunology ; Cell Nucleus/metabolism ; Cell Nucleus/virology ; Drug Design ; Host-Pathogen Interactions ; Humans ; Karyopherins/antagonists & inhibitors ; Karyopherins/metabolism ; Molecular Targeted Therapy ; Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors ; Receptors, Cytoplasmic and Nuclear/metabolism ; SARS-CoV-2/immunology ; SARS-CoV-2/pathogenicity ; COVID-19 Drug Treatment ; Exportin 1 Protein
    Chemical Substances Antiviral Agents ; Karyopherins ; Receptors, Cytoplasmic and Nuclear
    Keywords covid19
    Language English
    Publishing date 2020-06-20
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 1324988-5
    ISSN 1878-5832 ; 1359-6446
    ISSN (online) 1878-5832
    ISSN 1359-6446
    DOI 10.1016/j.drudis.2020.06.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4725: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Exportin 1 inhibition as antiviral therapy

    Uddin, Md Hafiz / Zonder, Jeffrey A / Azmi, Asfar S

    Drug discov. today

    Abstract: ... nucleocytoplasmic transport with exportin 1 (XPO1) inhibitors originally developed as anticancer drugs can quarantine key ... using the XPO1 inhibitor selinexor as a therapy for COVID-19 infection are in progress. ... and immunopathogenicity. These observations support the concept of the inhibition of nuclear export ...

    Abstract Coronavirus 2019 (COVID-19; caused by Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV-2) is a currently global health problem. Previous studies showed that blocking nucleocytoplasmic transport with exportin 1 (XPO1) inhibitors originally developed as anticancer drugs can quarantine key viral accessory proteins and genomic materials in the nucleus of host cell and reduce virus replication and immunopathogenicity. These observations support the concept of the inhibition of nuclear export as an effective strategy against an array of viruses, including influenza A, B, and SARS-CoV. Clinical studies using the XPO1 inhibitor selinexor as a therapy for COVID-19 infection are in progress.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #611872
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Identifying novel inhibitors targeting Exportin-1 for the potential treatment of COVID-19.

    Sharma, Tanuj / Mondal, Tanmoy / Khan, Sajid / Churqui, Marianela Patzi / Nyström, Kristina / Thombare, Ketan / Baig, Mohammad Hassan / Dong, Jae-June

    Archives of microbiology

    2024  Volume 206, Issue 2, Page(s) 69

    Abstract: ... we proved the inhibition of XPO1 as a therapeutic strategy for managing SARS-COV-2 and its variants ... spike positivity, suggesting inhibition of SARS-COV-2 infection. The outcome of this study could be ... The nuclear export protein 1 (XPO1) mediates the nucleocytoplasmic transport of proteins and ...

    Abstract The nuclear export protein 1 (XPO1) mediates the nucleocytoplasmic transport of proteins and ribonucleic acids (RNAs) and plays a prominent role in maintaining cellular homeostasis. XPO1 has emerged as a promising therapeutic approach to interfere with the lifecycle of many viruses. In our earlier study, we proved the inhibition of XPO1 as a therapeutic strategy for managing SARS-COV-2 and its variants. In this study, we have utilized pharmacophore-assisted computational methods to identify prominent XPO1 inhibitors. After several layers of screening, a few molecules were shortlisted for further experimental validation on the in vitro SARS-CoV-2 cell infection model. It was observed that these compounds reduced spike positivity, suggesting inhibition of SARS-COV-2 infection. The outcome of this study could be considered further for developing novel antiviral therapeutic strategies against SARS-CoV-2.
    MeSH term(s) Humans ; Active Transport, Cell Nucleus ; COVID-19 ; SARS-CoV-2 ; Exportin 1 Protein/antagonists & inhibitors
    Chemical Substances XPO1 protein, human ; Exportin 1 Protein
    Language English
    Publishing date 2024-01-19
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 124824-8
    ISSN 1432-072X ; 0302-8933
    ISSN (online) 1432-072X
    ISSN 0302-8933
    DOI 10.1007/s00203-023-03761-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 805: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top